Top Story

Enrollment begins for two trials of dabigatran

August 2, 2015

The first U.S. patients have been enrolled in the RE-DUAL PCI and RE-CIRCUIT trials of the safety and efficacy of dabigatran in patients with nonvalvular atrial fibrillation, according to a press release from Boehringer Ingelheim.

The event-driven, open-label RE-DUAL PCI trial will include approximately 8,520 patients with nonvalvular AF who have undergone PCI with stent placement. Patients will receive dabigatran (Pradaxa) 110 mg or 150 mg twice daily, in addition to antiplatelet therapy with clopidogrel or ticagrelor (Brilinta, AstraZeneca), or standard triple therapy with warfarin and two antiplatelet therapies. The primary efficacy endpoint is time to death, MI, stroke or systemic embolism and the primary safety endpoint is time to first major bleeding event. The endpoints will be assessed at several time points for up to 30 months after randomization. The trial will be conducted at 401 international centers. Results are anticipated in 2017, according to the release.

Trial assessing drug-coated balloon for PAD underway

August 1, 2015
The Spectranetics Corporation announced that enrollment is completed for the ILLUMNENATE Pivotal trial, which is evaluating the use of a drug-coated angioplasty balloon…
In the Journals

ADVICE: Adenosine-guided pulmonary vein isolation during AF ablation safe, effective

July 31, 2015
When adenosine testing was used to identify dormant pulmonary vein conduction in patients with atrial fibrillation undergoing catheter ablation, the rate of…
In the Journals

Self-expandable TAVR system yields low stroke rates

July 31, 2015
A self-expandable transcatheter aortic valve replacement system was associated with low early and late stroke rates in high-risk patients with aortic stenosis, according…

AAFP, ACP join nearly 600 other organizations in support of clinical data transparency

July 31, 2015
The American Academy of Family Physicians and the American College of Physicians has announced their support of the AllTrials campaign, joining 595 other organizations…
More News Headlines »
Highlights from Lipid Forum 2015™: Focus on Hypertriglyceridemia

Highlights from Lipid Forum 2015®: Focus on Hypertriglyceridemia

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent yet modifiable risk factor for atherosclerotic disease, pancreatitis, and…
More »
VIDEO: Joseph Rossano, MD, MS, discusses benefits of VADs for children with advanced HF

VIDEO: Joseph Rossano, MD, MS, discusses benefits of VADs for children with advanced HF

July 17, 2015
PHILADELPHIA — In this video, Joseph Rossano, MD, MS, FAAP, FAAC, medical director of HF/transplantation at…
More »
Oral Antiplatelet Therapy in a Patient with Acute Coronary Syndrome and Percutaneous Coronary Intervention

Case Study: Oral Antiplatelet Therapy in a Patient with ACS and PCI

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, over 780,000 persons annually will experience an acute coronary syndrome…
More »